LATEST
NEWS
Venture Café Londons torsdagssamling - 26. februar 2026
We're showcasing at Venture Café London’s Thursday Gathering, "From Research Gaps to...
Lær AMELIE-teamet at kende
The AMELIE YouTube channel is home to several video interviews where you can hear from members of...
AMELIE præsenterer ved Big Bowel Event 2024
The AMELIE research team was delighted to be invited to present at the Big Bowel Event on 22nd...
Spotlight på fækal inkontinens i Journal of Cell and Gene Therapy Insights
The causes and impacts of faecal incontinence are being highlighted in the latest edition of the...
Hvordan AMELIE kan imødekomme udækkede behov i behandlingen af afføringsinkontinens
Professor Charles Knowles, Clinical Chief Investigator of AMELIE Project, discusses our research...
Nye regenerative tilgange til behandling af afføringsinkontinens
Professor Richard Day is the Principal Investigator of the AMELIE project. He discusses how...
AMELIE-undersøgelse viser, at afføringsinkontinens betragtes som et alvorligt folkesundhedsproblem
Fækalinkontinens (FI) er en almindelig tilstand, der rammer omkring 67 millioner mennesker i Europa. Mange af disse mennesker kan være inkontinente på grund af en skade - ofte efter en fødsel. AMELIE's forskning i regenerativ medicin og celleterapi har til formål at hjælpe disse mennesker. Som en del af AMELIE-projektet brugte vi en undersøgelse til at finde ud af, hvad folk mener om FI og regenerativ medicin i forskellige europæiske lande.
Der skal gøres noget ved de store uligheder i behandlingen af bækkenbunden i Storbritannien
Bowel Research UK welcomes the findings of a new report which reveals significant short-comings in the care of UK patients with pelvic floor disorders (PFDs), and provides recommendations on six areas for change to improve outcomes.
Bækkenbundstjenester i Storbritannien skal ændres
A new report, ‘Seizing the opportunity to improve patient care: Pelvic Floor services in 2021 and beyond’ exposes significant shortcomings in the care of patients with pelvic floor disorders in the UK. It provides national and local recommendations to improve healthcare services.
Kan BOTOX-indsprøjtninger hjælpe på inkontinens?
For millions of Britons it is a secret they dare not discuss. A problem they put up with, silently, often for decades. Incontinence will affect 40 per cent of women, and one in ten men at some point in their lives.
Jiménez Díaz-fondens sundhedsforskningsinstitut deltager i et klinisk forsøg om behandling af afføringsinkontinens med celleterapi.
Fecal incontinence is a disease that affects some 67 million people in Europe. Although severity and presentation may be compatible with social life, it often overrides it entirely.
The latest to combat fecal incontinence: cell therapy
Fecal incontinence (FI) affects one in 20 Europeans. Although the severity and the way it presents itself are not life-threatening, this condition often ends up nullifying the social relationships of the people who suffer from it. And, its management continues to be a challenge for Medicine because a definitive optimal treatment for it has not yet been determined.
In search of a therapy against the disease that most affects social life
There are people who manage to live with it, but for most suffering fecal incontinence is synonymous with completely ending their social life, the main consequence of suffering from one of the diseases that cause the most stigma, as shown by never talking or writing about it subject.
AMELIE project: a new clinical study for CVBF
We are happy to announce that CVBF will be involved in the new project AMELIE – Anchored Muscle cELIs for IncontinencE aimed to test a new clinical approach for the treatment of faecal incontinence (FI) arising from childbirth injury in women.














